The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

GSK has failed to win the backing of influential advisers to the US drugs regulator for a key blood cancer drug, putting its ...

(Reuters) -GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

GSK said the U.S. Food and Drug Administration extended its review period for Blenrep combinations to treat patients with relapsed or refractory multiple myeloma.